AIM ImmunoTech Positions Ampligen as Potential Ebola Treatment Following WHO Emergency Declaration
Key Insights
AIM ImmunoTech is positioning its lead drug Ampligen as a potential treatment for Ebola virus disease amid the WHO's declaration of a Public Health Emergency of International Concern for the Bundibugyo strain outbreak.
Pre-clinical studies conducted at USAMRIID Biosafety Level 4 laboratories demonstrated 100% survival protection in mice following lethal Ebola virus exposure when Ampligen was administered early after infection.
The company plans to release findings on Ampligen's potential as an early treatment for Ebola virus disease, highlighting its mechanism as a TLR3 (search) agonist that blocks viral dsRNA binding.
AIM ImmunoTech Inc. is positioning its lead drug Ampligen (rintatolimod) as a potential treatment for Ebola virus disease following the World Health Organization's declaration of a Public Health Emergency of International Concern for the ongoing Bundibugyo strain outbreak in Central and East Africa. The company announced it will present previously published pre-clinical findings supporting Ampligen's potential role as a prophylactic and early-onset antiviral treatment for Ebola virus disease.
Pre-Clinical Efficacy Data
Research conducted at the United States Army Medical Research Institute of Infectious Diseases (USAMRIID) Biosafety Level 4 laboratories demonstrated significant protective effects of Ampligen against Ebola virus infection. The peer-reviewed study, titled "Ebola virus disease: In vivo protection provided by the PAMP restricted TLR3 (search) agonist rintatolimod and its mechanism of action," reported 100% survival protection in a mouse model that is otherwise 100% lethal when Ampligen was administered early following infection.
The study findings showed that protection from Ebola in mice was achieved at a dose of 6 mg/kg, a dosage that is generally well-tolerated in humans. According to AIM CEO Thomas K. Equels, "The research demonstrated 100% protective survival, compared to 100% mortality in the lethal Ebola virus disease model."
Mechanism of Action
The research revealed that Ampligen acts through a specific mechanism involving TLR3 (search) activation. The drug blocks EBOV VP35 (search) viral dsRNA binding and functions as a PAMP restricted agonist for direct TLR3 activation, while not acting as a RIG-1-like agonist. This mechanism of action positions Ampligen as a highly selective TLR3 agonist immuno-modulator with broad-spectrum antiviral activity.
Current Outbreak Context
The announcement comes as health authorities face mounting international concern over the rapidly evolving Ebola outbreak involving the Bundibugyo strain currently spreading in parts of Central and East Africa. The WHO's declaration of a Public Health Emergency of International Concern underscores the urgent need for effective countermeasures against this strain, for which there is currently no approved specific treatment or vaccine.
Global public health authorities are warning of increased cross-border transmission risk, prompting healthcare systems and biodefense agencies to actively evaluate scalable antiviral and immune-based therapeutic strategies capable of responding to emerging viral threats.
Regulatory Status and Development Pathway
Ampligen has previously received Orphan Drug designation for Ebola virus disease from both the U.S. Food and Drug Administration and the European Medicines Agency. This regulatory recognition provides a foundation for potential accelerated development pathways in the current outbreak environment.
"We believe these findings are especially relevant given the current Bundibugyo outbreak, which currently lacks an approved targeted therapeutic option," stated CEO Equels. "Ampligen's mechanism of action may position it as a potentially important countermeasure to help protect health care workers and other vulnerable populations both before and shortly after exposure."
Strategic Positioning
AIM ImmunoTech believes the current outbreak environment may create opportunities for additional Biosafety Level 4 research access, collaborations, and regulatory engagement in developing Ampligen as a therapeutic for Ebola virus disease. The company anticipates that Ampligen's demonstrated antiviral and immune-modulating properties could attract significant interest from international health organizations, biodefense agencies, and potential strategic partners.
The company plans to release a Virtual Investor "Ebola: What This Means" segment that will review Ampligen's mechanism of action, pre-clinical Ebola findings, and potential development pathways in emerging viral disease preparedness and response initiatives.